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ABSTRACT 
AIM 
Information resulting from oesophageal 24h pH-impedance monitoring (pH-MII) may have 
important consequences for patients’ management. 
Aims of this study were 1) to evaluate agreement for number of reflux episodes and symptom/reflux 
association indexes in MII-pH tracings analysis between and within three experienced observers 
working in different European Centers, 2) to evaluate the predictivity of a shorter manual analysis 
targeted to the two-minutes window periods before each symptomatic episode with regards to the 
traditional. 
MATERIALS AND METHODS 
Forty consecutive pH-MII tracings of patients (23 women, median age 55 years) referred for 
suspected oesophageal (n=24) or extra-oesophageal (n=16) GORD symptoms in two Northern 
Italian Centers were included (20 tracings/Center). After automatic analysis (MMS, Enschede, The 
Nederlands), tracings were duplicated and anonymized. Three expert observers blindly performed 
the traditional manual analysis on the 40 duplicated tracings, erasing or adding reflux episodes 
according to their judgment based on the Oporto Criteria. The first manual analysis was performed 
in a sequential order, the second one in a randomly assigned order. Subsequently a short manual 
analysis was also blindly performed. Values of both symptom association indexes (Symptom 
Index=S.I. and Symptom Association Probability=S.A.P.) were transformed into binary response 
(i.e. positive or negative). Inter- and intra-observer agreement was calculated with Cohen’s 
Coefficient (k) and/or with percentage of agreement.    
RESULTS 
Inter-observer agreement on acid reflux was excellent between the three observers for both S.I. and 
S.A.P. (K=1.0; 100%), whereas considering non-acid reflux it was high for S.I. (95%, 92.5% and 
95% of concordance for observer 1,2 and 3 respectively) and moderate for S.A.P. (K=0.35; 85% 
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between observer 1 and 2, K=0.36; 82.5% between observer 1 and 3, K=0.23; 87.5% between 
observer 2 and 3). 
Intra-observer agreement on acid reflux was good to excellent for both S.I. (K=0.77; 95% for 
observer 1 and 2 and K=1.0; 100% for observer 3), and S.A.P. (K=0.80; 95% , K=0.72; 92.5% and 
K=1.0; 100% for observer 1, 2 and 3 respectively). Intra-observer agreement on non-acid reflux was 
high for S.I. (97.5%, 95% and 97.5% of concordance for observer 1, 2 and 3 respectively) and 
moderate for S.A.P. (K=0.48; 85% and K=0.54; 90% for observer 1 and 3 and good for observer 2, 
K=0.79; 2.5%). 
Considering all the three observers the short analysis was predictive of the traditional one for both 
S.I., 88% and 98% of the tracings for acid and non-acid reflux, respectively and S.A.P., 99% and 
97% of the tracings for acid and non-acid reflux, respectively. 
CONCLUSIONS 
We found a good inter- and intra-observer agreement for symptom/reflux association indexes, 
especially when considering acid reflux. Moreover we demonstrated that short analysis was highly 
predictive of the traditional manual analysis, suggesting that the short one could be used in routine 
clinical practice with considerable savings. 
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GASTRO-OESOPHAGEAL REFLUX DISEASE 
DEFINITION, EPIDEMIOLOGY AND CLINICAL MANIFESTATIONS 
Gastro-oesophageal reflux disease (GORD) is a condition which develops when reflux of gastric 
contents causes troublesome symptoms and/or complications (1). While this is still predominantly a 
disease of the Western population (prevalence at 10-15%), changing dietary patterns, the global 
increase in obesity and other causes have led to a pronounced increase in the prevalence of GORD 
in Asia. This disease therefore has a global impact on health and impairs health related quality of 
life of a substantial proportion of the world’s population. According to the Montreal definition and 
classification (1), the clinical manifestations of GORD include: 
- typical reflux syndrome (heartburn and/or regurgitation) 
- reflux chest pain syndrome 
- extra-oesophageal syndrome (chronic cough, chronic laryngitis, asthma, dental erosions) 
- syndromes with oesophageal injury: erosive oesophagitis, reflux strictures, Barrett’s oesophagus, 
oesophageal adenocarcinoma. 
Symptoms of reflux disease are not completely specific and often co-exist with other 
gastrointestinal symptoms. Identification of the dominant symptom by either patient or clinician 
may be difficult. The accuracy of heartburn as a diagnostic symptom for reflux disease is somewhat 
unclear, however results of empirical PPI therapy in patients with reflux disease and heartburn as 
their predominant symptom suggest that the sensitivity ranges from 70% to 80% with a specificity 
of 55-65% (2, 3). The presence of regurgitation appears to strengthen the diagnostic accuracy of 
heartburn (4). The prevalence of chest pain in patients with reflux disease is unknown, however the 
presence of non-cardiac chest pain is highly predictive of underlying GORD, with 21% of such 
patients having oesophagitis on endoscopy, 42% having abnormal acid exposure time, and 39% 
having a positive association between chest pain and reflux episodes during pH monitoring (5-8). 
The value of extra-oesophageal symptoms in the diagnosis of reflux disease is questionable. Current 
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evidence suggests that only in patients with typical reflux symptoms, in addition to extra-
oesophageal symptoms, extra-eoesophageal symptoms respond to antireflux therapy (9, 10). 
 
DIAGNOSIS 
Upper GI endoscopy is the gold standard to identify oesophageal erosions, the hall-mark feature of 
erosive reflux disease. Recent studies however document that up to 70% of patients with 
oesophageal symptoms have normal endoscopic findings in the oesophagus (11). In addition, 
empiric proton pump inhibitor (PPI) therapy trials are used in the primary care setting as the first 
step to evaluate patients with symptoms suggestive of GORD (12). Symptom response to PPI 
therapy establishes the diagnosis of GORD with a sensitivity of 75-92% and specificity of 55-90% 
(7, 13, 14). Patients with persistent oesophageal symptoms on acid suppressive therapy are 
considered patients with refractory GORD (15) and fall into one of the 3 categories: 1) patients with 
inadequate acid suppression on standard dose PPI in whom symptoms are related to acid reflux, 2) 
patients with adequate acid suppression on standard dose PPI but with an abnormal number of 
reflux episodes in whom symptoms are related to non-acid reflux and 3) patients with oesophageal 
symptoms independent of gastro-oesophageal reflux. These patients deserve laboratory based 
investigations, which are performed in specialized GI function laboratories and aim at identifying 
abnormal amounts of gastro-oesophageal reflux in the oesophagus and/or clarify the relationship 
between oesophageal symptoms and gastro-oesophageal reflux episodes. Most commonly used 
oesophageal reflux monitoring investigations include oesophageal pH monitoring (catheter-based 
and wireless) and the more recently developed impedance-pH monitoring (the latter one will be 
described in the next chapter). 
 
Oesophageal pH monitoring 
Despite methodological limitations, conventional pH monitoring is still very accurate in quantifying 
distal oesophageal acid exposure. In patients off acid suppressive therapy this is still considered the 
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gold standard to diagnose or exclude GORD. Another important indication is the oesophageal pH 
testing in the pre-operative setting, i.e. before surgical or endoscopic therapy for reflux. 
Prior to reflux monitoring, calibration of pH sensors using reference buffer solutions needs to be 
performed. Two calibration substances are usually used – one in the acidic range (pH 1-4) and one 
in the neutral range (pH 6-7). 
By convention, catheter-based pH electrodes are positioned five cm above the proximal border of 
the lower oesophageal sphincter (LOS) (16, 17). After the correct placement of pH electrodes, 
patients are asked to undergo the same daily routines as usual and to reproduce situations that cause 
the symptoms for which they have undergone reflux monitoring, in order  to maximise the ability of 
pH monitoring to evaluate the relationship between symptoms and reflux. 
The capsule pH system is a catheter-free oesophageal pH monitoring system, which consists of an 
antimony pH electrode, a radio transmitter and a battery contained in a capsule. The data from the 
capsule are transmitted by telemetry to a portable digital recorder clipped onto the patient’s belt. 
Capsule placement is accomplished with the aid of a delivery device, usually during an upper 
endoscopy and conventionally placed six cm above the squamocolumnar junction. The two main 
advantages of this device are 1) no catheters in the patients throat or nose, thus reducing discomfort 
and improving adherence to daily activities; 2) longer monitoring (usually 48 hours and up to 96 
hours) (18). 
Intraoesophageal pH monitoring, regardless whether catheter-based or wireless, identifies gastro-
oesophageal reflux episodes as abrupt drops in pH from above to below 4.0. The parameters more 
often analysed during oesophageal pH monitoring, in order to determine if a patient has abnormal  
oesophageal reflux, are: 
- total oesophageal acid exposure time (percentage of time at pH < 4.0) 
- upright oesophageal acid exposure time (percentage of time at pH < 4.0) 
- supine oesophageal acid exposure time (percentage of time at pH < 4.0) 
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Moreover, symptom indices are important components of assessing the relationship between reflux 
and patients symptoms. The two main symptom indices include the Symptom Index (S.I.) i.e. the 
percentage of symptom episodes that are related to reflux, which is considered positive if > 50% 
(19), and the Symptom Association Probability (S.A.P.), which is a more complex index indicating 
that the association between reflux and symptoms does not occur by chance and is considered 
positive if > 95 (20). 
 
TREATMENT 
PPIs represent the main treatment in GORD and cause symptom relief in 70-80% of patients. 
Because most reflux episodes, both acidic and non-acid, result from transient LOS relaxation 
(TLOSR), i.e. complete and long lasting relaxations of the LOS that are not preceded by swallows, 
controlling occurrence of TLOSRs appears to be a relevant therapeutic target in GORD patients 
refractory to PPIs. The most popular available anti-reflux therapy which is able to reduce TLOSRs 
occurrence is surgery (i.e. fundoplication). Regarding pharmacological compounds, GABAb 
agonists and the mGluR5 antagonists were the most promising, however they have not been 
introduced in clinical practice because of both the unsatisfactory performance in controlling GORD 
symptoms and their important side effects. 
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COMBINED 24-h MULTICHANNEL INTRALUMINAL IMPEDANCE-pH 
MONITORING  
In recent years the increasing number of patients with persistent symptoms on acid suppressive 
therapy revealed the limitations of single pH monitoring in order to detect gastro-oesophageal 
reflux. A further development has been multichannel intraluminal impedance (MII), first described 
by Silny et al in 1991 (21). MII monitoring detects changes in intraluminal electrical conductivity of 
the oesophageal content providing information on presence of liquids and gas in the oesophagus. 
The basic component of MII technology is an impedance circuit. Alternating electrical current is 
applied between two metal rings mounted on a catheter which acts as an electrical isolator. In an 
empty oesophagus the system will measure a baseline oesophageal impedance of 1500-2000 Ohm. 
The appearance of liquid bolus in the impedance measuring segment leads to a decline in 
impedance from baseline, decline that persists as long as the bolus is present between the pair of 
metal rings. Once the liquid has been cleared from this segment, impedance returns back to its 
baseline value. Incorporating multiple impedance measuring segments allows detecting the 
direction of bolus movement: a rapid decline in intra-oesophageal impedance starting in the 
proximal channels and advancing over time to the distal channel indicates bolus movement in 
anterograd (aboral) movement. Vice versa a decline starting in the distal oesophagus and moving 
towards the proximal oesophagus indicates bolus transit in retrograde (oral) direction. The 
differentiation in direction of bolus movement allows identification of swallows (anterograde) and 
reflux events (retrograde). Combining multichannel intraluminal impedance with pH monitoring 
(i.e. impedance-pH) becomes an important tool to identify and validate gastro-oesophageal reflux 
episodes of all types, independently of their acidity (22). In particular, gastro-oesophageal reflux 
episodes detected by MII may be differentiated in acidic (if pH drops below 4.0), weakly acidic (if 
pH is between 4.0 and 7.0) and weakly alkaline (if intra-oesophageal pH during an MII-detected 
reflux episode is above 7.0) (23). Further studies are required to clarify the clinical relevance of 
separating non-acid reflux into weakly acidic and weakly alkaline. 
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Oesophageal impedance-pH monitoring systems use a thin flexible catheter similarly to 
conventional pH monitoring. The procedure of transnasal insertion of the catheter with intubation of 
oesophagus and stomach, duration of measurement and patient activities does not differ from 
standard 24-h pH monitoring. Besides a pH sensor, multiple rings are mounted on the catheter and 
electrical impedance data are measured between two adjacent rings. The most common design used 
in clinical practice incorporates impedance rings placed at 2, 4, 6, 8, 10, 14, 16 and 18 cm and a pH 
sensor at 5 cm from the tip of the catheter. This catheter therefore collects impedance data at 3, 5, 7, 
9, 15 and 17 cm above the LOS in addition to pH data at the usual position 5 cm above the LOS 
(figure 1). During monitoring, the MII-pH catheter is connected to an external data logger and data 
are sampled at 50 Hz. Data are stored on a flash memory card and transferred to a computer work 
station with dedicated interpretation software after the monitoring period. 
Combined MII-pH monitoring provides information on: 1) the number of gastro-oesophageal reflux 
episodes (both acid and non-acid), 2) the physical condition of reflux episodes (i.e. liquid, gas or 
mixed liquid-gas), 3) the height of the reflux column inside the oesophagus and 4) the association 
between symptoms and reflux episodes (i.e. using S.I. or S.A.P.).  
The importance of gastric acid in the development of oesophageal mucosal erosions is well 
established. Reducing the acid content as done by PPI therapy has shown healing rates close to 90% 
in GORD (24). On the other hand, non-acid reflux is currently considered to be a relevant cause of 
symptoms in patients refractory to PPIs rather than having a major role in causing oesophagitis. 
This is important as one third of patients diagnosed with erosive GORD (24) and up to 65% of 
patients with non-erosive GORD have persistent symptoms on daily dose of PPI independent of 
endoscopic integrity (25). 
Maine et al (26) and Zerbib et al (27) documented that oesophageal symptoms during 24h combined 
MII-pH monitoring were associated with ongoing gastro-oesophageal reflux in up to 50% of 
patients on therapy with PPI twice daily. Recently Backer et al (28) have evaluated patients with 
ongoing symptoms under acid suppressive therapy and found abnormal MII-pH findings (abnormal 
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distal oesophageal acid exposure or abnormal number of MII-detected reflux episodes) in 39% of 
patients taking standard dose PPI once daily. Patients were followed up for at least 3 months after 
the dose of PPI was increased. The authors were able to document a significantly better 
symptomatic relieve in patients with abnormal MII-pH results (90%) compared to patients with 
normal MII-pH findings (43%), concluding that combined MII-pH monitoring facilitates a more 
focused therapeutic approach to patients with PPI-resistant GORD possibly avoiding PPI overuse. 
Whereas pH-monitoring analysis is automatic and very quick, analysis of MII-pH tracings is much 
more time consuming because it needs manual revision of tracings after the automatic analysis as 
events other than reflux are included among reflux episodes by the software. In particular automatic 
analysis overestimates the number of non-acid reflux events resulting in a lower sensitivity and 
specificity of a positive symptom/reflux association index (S.I. and/or S.A.P.) compared to visual 
analysis (29).  Moreover, the presence of low baseline impedance, as observed in presence of 
erosive oesophagitis or Barrett’s oesophagus (30, 31), makes the analysis more difficult and 
mistakes easier to occur. These considerations are of relevance because information resulting from 
MII-pH is important, guiding medical and eventually surgical treatment. However, studies on inter- 
and intra-observer agreement of manual analysis are scanty in the adult population (32), whereas a 
few data are available in children (33, 34) and they have not focused on symptom/reflux association 
analysis. Finally the introduction of a shorter manual analysis would be a valid attempt to save 
physician’s time and Health Care System money. One way to do it would be to concentrate own 
attention on the short window periods before each symptomatic episode, however so far there are no 
data.   
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AIM 
Therefore, aims of this study were: 1) to evaluate agreement for number of reflux episodes and 
symptom/reflux association indexes in MII-pH tracings analysis between and within three 
experienced observers working in different European Centers, 2) to evaluate the predictivity of  a 
shorter manual analysis targeted to two-minutes window periods before each symptomatic episodes 
with regards to the traditional analysis. 
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MATERIALS AND METHODS 
PATIENTS POPULATION  
Between September 2011 and January 2012 forty consecutive patients off PPI therapy with typical 
(i.e. heartburn and regurgitation) and/or atypical (i.e. chest pain) oesophageal or extra-oesophageal 
(i.e. cough and hoarseness) symptoms possibly related to GORD, who have undergone 24h MII-pH 
in two Centers in Northern Italy and have reported symptoms during the test, were prospectively 
enrolled. Each Center has provided 20 MII-pH tracings. The study protocol has been approved by 
the Ethics Committees of both hospitals.  
 
IMPEDANCE-pH EQUIPMENT  
Oesophageal impedance-pH monitoring was performed using a multi-channel intraluminal 
impedance-pH ambulatory system, including an MII-pH catheter (pHersaflex®, Sierra Scientific 
Instruments, CA, USA) containing one distal antimony pH electrode and eight impedance 
electrodes rings at 2, 4, 6, 8, 10, 14, 16 and 18 cm from the tip of the catheter, and a portable data-
logger with impedance amplifier (Medical Measurement Systems, Enschede, The Netherlands). 
 
STUDY PROTOCOL  
After an overnight fast, patients attended the Upper GI Physiology Unit of both Centers. Patient’s 
medical history was collected and informed consent was signed. The LOS was located by 
oesophageal manometry and the impedance-pH catheter was passed transnasally under topical 
anaesthesia and positioned with the pH electrode 5 cm above the upper border of the LOS. During 
the MII-pH monitoring, patients were asked to report timing of meals and periods spent in 
recumbent position on a daily diary card; when a symptom occurred patients were asked to push a 
button on the portable receiver and to report the exact time on the diary card. When many 
symptoms were reported, only the principal symptom was taken into account. During the recording 
period patients were allowed to have a free diet, except for known acidic food and beverages, and to 
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continue their usual daily activities. Patients returned to the Upper GI Physiology Unit on the 
following morning for catheter removal.  
 
DATA ANALYSIS 
Data stored on the Compact Flash Card were downloaded into a personal computer. Markers of 
meal periods and of timing in recumbent position were manually inserted. Data were analysed by 
using an automated reflux detection algorithm (Medical Measurement Systems, Enschede, The 
Netherlands) and meal periods were excluded from the analysis. Original tracings were anonimyzed 
and numbered from 01 to 20 (provided by Milano) and from 41 to 60 (provided by Verona) for 
inter-observer agreement analysis (first analysis). These tracings were subsequently duplicated and 
numbered in a randomised order from 21 to 40 and from 61 to 80 for intra-observer agreement 
analysis (second analysis). Each tracing was named adding a code identifying the Center in order to 
distinguish those reviewed by each observer (observer 1 from Milano, observer 2 from Verona and 
observer 3 from London). In order to identify tracings difficult to analyse, before performing 
manual analysis, baseline impedance of each tracing was measured. Oesophageal baseline 
impedance was assessed as a mean baseline at the two most distal impedance channels (situated at 3 
and 5 cm above the LOS), considering a five-minutes window period during the night. Manual 
analysis (traditional analysis) was performed as follows. At first each observer went through every 
reflux episode; when the observer did not agree with the automatic analysis, the reflux episode was 
erased. Afterwards the observer went through the two-minutes window period preceding each 
symptom marked by the patient in order to identify reflux episodes possibly missed by the 
automatic analysis. A short manual analysis was also performed as follows: for every tracing, using 
a separate automated analysis file, each observer erased or added only the reflux episodes in the 
two-minutes window period preceding each symptom, on the basis of the traditional analysis he/she 
had already done.  
The three observers were all experienced in analyzing MII-pH tracings.  
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DEFINITIONS OF REFLUX EPISODES 
Liquid reflux was defined as a retrograde 50% drop in impedance, starting at the level of the LOS 
and propagating to at least the next two more proximal impedance-measuring segments. Only liquid 
reflux lasting at least 3 seconds were taken into account. Gas reflux was defined as a rapid (3 
kΩ/second) increase in impedance > 5000 Ω, occurring simultaneously at least in two oesophageal 
measuring segments, in the absence of swallowing. Mixed liquid-gas reflux was defined as a gas 
reflux occurring immediately before or during a liquid reflux.  
Reflux episodes were characterized by pH drop nadir in: (1) Acid reflux: impedance-detected reflux 
event with a nadir pH less than 4 (2) Weakly acid reflux: impedance-detected reflux event with a 
nadir pH between 4 and 7 (3) Weakly alkaline reflux: impedance-detected reflux event with a nadir 
pH above 7. This classification is according to a recently published consensus report (22). As 
weakly alkaline refluxes are very unfrequent, in the analysis they were merged with weakly acidic 
refluxes and considered as non-acid reflux.  
  
GASTROESOPHAGEAL REFLUX PARAMETERS 
Impedance and pH data were analysed during both upright and supine positions; meals were 
excluded from the analysis. Data were used to calculate the number and type of reflux events.  
Total number of reflux episodes was considered pathological when > 75/24 hours, whereas was 
considered normal when < 75 (35). 
 
SYMPTOM/REFLUX ASSOCIATION ANALYSIS 
S.I. and S.A.P. have been automatically calculated by the software in each patient. Only the 
association between the principal symptom reported by the patient and acid and non-acid reflux 
were reported. S.I. and S.A.P. were defined according to Wiener et al. and Weusten et al, 
respectively (19, 20). S.I. was considered positive when > 50% and S.A.P. when > 95. 
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STATISTICAL ANALYSIS 
All data processing and analyses were carried out with SAS statistical 
software (version 9.2; SAS Institute, Cary, NC, USA). 
Data are presented as median (interquartile range). Inter-observer and intra-observer agreement 
were assessed by using Cohen’s kappa (k) with standard error (SE) and/or expressed as percentages 
of agreement when the table was not squared . By convention, a kappa between 0.81 and 1.00 is 
interpreted as indicating excellent agreement. Values of <0.20, 0.21-0.40, 0.41-0.60 and 0.61-0.80 
are interpreted as showing poor, fair, moderate and good agreement, respectively. 
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RESULTS 
PATIENTS CHARACTERISTICS  
Twenty three of the forty enrolled patients were women and the median age was 55 years (range: 
19-71). All the patients completed the study and the recording period was more than 23 hours in all 
of them. Seventeen patients (42.5%), 7 patients (17.5%) and 16 patients (40%) experienced typical 
oesophageal, atypical oesophageal and extra-oesophageal symptoms, respectively. Concerning 
symptoms frequency, half of the patients (20/40; 50%) reported less than 4 symptoms and half of 
them more or equal than 4 symptoms during the recording period. No patients had a low 
oesophageal impedance baseline, the median value being 2487 Ω (range: 662-5548 Ω). Table 1 
shows variables of the 40 MII-pH tracings as assessed by the 3 observers. The total number of 
reflux episodes was more than 75 in 5/40 (12.5%), 2/40 (5%) and 5/40 (12.5%) tracings for 
observer 1, 2, 3, respectively. 
 
AGREEMENT FOR DETECTION OF REFLUX EPISODES 
 
Inter-observer (table 2) 
When considering all reflux episodes together agreement between the observers was high for acid 
refluxes and lower for non-acid ones. Table 2 shows the inter-observer agreement between the 
observers with regards to the number of reflux episodes divided into acid/non acid and liquid/mixed 
refluxes. When considering acid reflux, inter-observer agreement was good to excellent, K values 
being 0.69 between observer 1 and 2, 0.72 between observer 2 and 3 and 0.89 between observer 1 
and 3, respectively; when considering non-acid reflux, inter-observer agreement was moderate, 
K=0.32 between observer 1 and 2, K= 0.36 between observer 2 and 3 and K=0.40 between observer 
1 and 3, respectively.  Inter-observer agreement for number of liquid and mixed reflux episodes was 
similar. 
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Intra-observer (table 3) 
When considering all reflux episodes together intra-observer agreement was moderate for observer 
1, K=0.40, whereas it was good for observer 2 and 3, K=0.84 and K=0.77, respectively. Table 3 
shows the intra-observer agreement between the first and the second analysis with regards to the 
number of reflux episodes divided into acid/non acid and liquid/mixed refluxes. When considering 
acid reflux, intra-observer agreement was good to excellent, K values being 0.64, 0.68 and 0.85 for 
observer 1, 2 and 3, respectively; when considering non-acid reflux, intra-observer agreement was 
excellent, K=0.84 for observer 2 whereas was moderate for observer 1 and 3, K=0.32 and K=0.40, 
respectively. Intra-observer agreement for number of liquid and mixed reflux episodes was 
similarly moderate for observer 1 and 3 and good for the observer 2. 
Intra-observer agreement for judging a study normal or pathological on the basis of the number of 
reflux episodes was almost perfect for all the observers, as the number of studies with a 
pathological number of reflux episodes remained the same for observer 2 and increased from 5 to 
6/40 for observer 1 and 3 in the second analysis. 
 
AGREEMENT FOR SYMPTOM/REFLUX ASSOCIATION ANALYSIS 
 
Inter-observer (table 4) 
Agreement between the three observers was high for acid refluxes and lower for non acid ones 
(table 4). In particular when considering acid reflux, inter-observer agreement between the 
observers was excellent for both S.I. and S.A.P., being K=1.0. When considering non-acid reflux, 
inter-observer agreement between the observers was moderate for S.A.P., being K=0.35 between 
observer 1 and 2, K=0.36 between observer 1 and 3, K=0.23 between observer 2 and 3. K value for 
inter-observer agreement  between the observers for S.I. was not measurable because the table was 
not squared; however the percentage of agreement between the observers was > 92.5%.  
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Intra-observer (table 5) 
Agreement between the first and the second analysis was generally high for all three observers 
(table 5). When considering acid reflux, intra-observer agreement was good to excellent for both 
S.I., K=0.77 for observer 1 and 2 and K=1.0 for observer 3, and S.A.P., K=0.80, K=0.72 and K=1.0 
for observer 1, 2 and 3, respectively. When considering non acid reflux intra-observer agreement 
for S.I. was not measurable because the table was not squared; however the percentage of 
agreement was > 95% for each observer. Intra-observer agreement for S.A.P. was moderate for 
observer 1 and 3, K=0.48 and K=0.54 and remained good for observer 2, K=0.79.  
 
PREDICTIVITY OF A SHORT ANALYSIS  
Short analysis showed a high predictivity of the traditional one although a bit lower for S.I. for acid 
reflux (table 6). Regarding S.I. the percentage of agreement for acid reflux was 87.5%, 90% and 
87.5% for observer 1, 2 and 3, respectively, whereas it was higher for non acid reflux, being 100%, 
95%, and 100% for observer 1, 2 and 3 respectively. Regarding S.A.P. the percentage of agreement 
for acid reflux were 100%, 97.5% and 100% for observer 1, 2 and 3 respectively, and for non acid 
reflux were 97.5 %, 92.5 % and 100 % for observer 1, 2 and, 3 respectively.  
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DISCUSSION 
The major finding of this study was that, in MII-pH tracings analysis of patients with GORD, inter- 
and intra-observer agreement for number of acid reflux episodes and for symptom/reflux 
association indexes (i.e. S.I. and S.A.P.) for acid reflux was high, whereas was lower for non acid 
reflux. Another important finding of this study was that a short manual analysis was highly 
predictive of the traditional one.  
So far only few studies are available on inter- and intra- observer agreement analysis and all of 
them focused on agreement for number of reflux episodes; no studies on agreement for 
symptom/reflux association indexes and on predictivity of a short versus the traditional analysis are 
reported. 
Our study demonstrated that inter-observer agreement for number of reflux episodes was good. 
When considering separately acid and non-acid reflux, we observed that agreement remained good 
for acid reflux but it became poorer for non-acid reflux. A possible explanation of this finding could 
be that non-acid refluxes are more challenging to be evaluated, therefore the observer is tempted to 
erase them more frequently than acid refluxes which are easier to be interpreted for the presence of 
pH drop below 4. In particular the observer of the Verona Center was more restrictive in the 
acceptance of an event as non acid reflux. In the multi-center pediatric study conducted by Loots et 
al (34), inter-observer agreement for number of reflux episodes was lower (K=0.46) than ours as 
only 42% of the reflux episodes were confirmed by the majority of the ten observers; moreover the 
authors did not evaluate whether inter-observer agreement differed between acid and non-acid 
reflux. In another multi-center study conducted in the pediatric population four observers reviewed 
24 tracings and the authors found an excellent inter-observer agreement (k=0.84), however each 
tracing was analyzed only by two reviewers and again differences between acid and non acid reflux 
were not evaluated (33). The only study performed in the adult population showed a good mean 
inter-observer agreement (K=0.72) for number of reflux episodes (32); an important limit of this 
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study was that each tracing was assessed by four reviewers from the same institution and probably 
trained by the same person, thus introducing a potential bias in agreement results.  
Concerning intra-observer agreement for number of reflux episodes, we found a moderate to 
excellent agreement depending on observers. Intra-observer agreement was higher for acid refluxes 
than for non acid refluxes for observer 1 and 3, whereas it was the contrary for observer 2. Loots et 
al. (34) evaluated the intra-observer agreement for number of reflux episodes only in three of the 
ten observers and they showed agreements’ values similar to ours but, as previously reported, a 
subanalysis on acid and non acid refluxes was not performed. Pilic et al. (33) found a good median 
intra-observer agreement (k=0.88), although it was calculated in only 6 of the 24 tracings 
performed, whereas the only other study conducted in the adult population did not evaluate intra-
observer agreement (32). 
Agreement for judging a study normal or pathological on the basis of number of reflux episodes 
was high in our study. However this is only a descriptive report that should be cautiously 
interpreted because in the majority of the patients the number of reflux episodes detected was lower 
than 75. In the series reported by Loots et al. (34) half of the ten tracings analyzed by their 
observers had the number of reflux episodes lower than 75, although a substantial agreement (k= 
0.70) in defining a study normal or pathological was found. However the authors pointed out that 
this result can be considered poor when being used to guide clinical decision making. 
So far, our is the first multi-center study reporting the agreement on symptom/reflux association 
indexes for both acid and non acid reflux. As it could be expected inter-observer agreement between 
the observers for S.I. and S.A.P. for acid reflux was excellent. Conversely, inter-observer agreement 
for non acid reflux was fair, reflecting the lower agreement in evaluation of number of non acid 
refluxes than acid ones. Moreover, intra-observer agreement for S.I. and S.A.P. for acid reflux was 
good to excellent, remaining good for S.A.P. for observer 2 but becoming moderate for observer 1 
and 3 for non-acid reflux. This trend reflects the intra-observer agreement for number of reflux 
episodes previously described and this finding support the assumption that non acid refluxes are 
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more challenging to be evaluated even by experienced observers. This evidence should move the 
factories to improve the software used for automatic analysis on one hand and to improve the 
training of the new reviewers who wants to approach this technique on the other. Concerning the 
last point, consensus among experts with the purpose to better define MII-pH criteria in order to 
evaluate reflux episodes should be planned (34). A possible limitation of analysis for agreement on 
symptom/reflux association indexes could be the low number of patients with positive S.I. or S.A.P. 
As a matter of fact S.I. was positive in 17.5%, 12.5% and 15% of the tracings for observer 1, 2 and 
3, respectively and S.A.P. in 35%, 17.5% and 27.5% of the tracings for observer 1, 2 and 3, 
respectively. However it needs to be pointed out that our patients are representative of those 
referred to a Tertiary Center and they were similar between the two Centers regarding S.I. and 
S.A.P. variables .   
In our study no tracings difficult to analyse were found based solely on impedance baseline, as 
median impedance baseline was 2487 Ω (range: 662-5548 Ω) because none of the patients had 
severe erosive oesophagitis or Barrett’s oesophagus. Impedance baseline was measured considering 
a five-minutes window period during night-time, as Kessing et al. showed that impedance baseline 
did not differ between daily and night period (31). Loots et al reported a better agreement for 
number of reflux episodes when easy tracings were compared to challenging ones (i.e. the ones with 
low baseline impedance). Probably other impedance variables can be assessed in order to consider a 
tracing difficult to be analyzed (i.e. unstable baseline) as recently proposed by Loots et al. (34) but 
they were not be considered in our study. 
Finally, to our knowledge this is the first study evaluating the predictivity of a short analysis 
compared to the traditional one. Short analysis showed high concordance with the traditional one 
for both S.I. and S.A.P. for acid and non acid reflux. This is a very important finding because 
manual MII-pH analysis is a time consuming procedure.  
In conclusion our study has demonstrated a good inter- and intra-observer agreement for number of 
reflux episodes detection and for symptom/reflux association indexes, especially when considering 
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acid reflux. Moreover, high concordance was found for symptom/reflux association indexes 
between a short manual analysis, less time-consuming, and the longer time-consuming traditional 
analysis, suggesting that the short one could be used in routine clinical practice to save physician’s 
time and Health Care System money. 
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TABLES 
Table 1. Variables of the 40 MII-pH tracings as assessed by the three observers. 
 Observer 1 
(Milano) 
Observer 2 
(Verona) 
Observer 3 
(London) 
AC reflux episodes (n)  25 (1-90) 22 (0-83) 25 (1-91) 
NA reflux episodes (n) 19 (2-89) 8 (1-76) 21 (2-99) 
Total reflux episodes (n) 44 (1-90) 30 (0-83) 46 (1-99) 
Positive SI for AC, (%) 5 (12.5) 5 (12.5) 5 (12.5) 
Positive SI for NA, (%) 2 (5) 0 (0) 1 (2.5) 
Positive SAP for AC, (%) 6 (15) 5 (12.5) 6 (15) 
Positive SAP for NA, (%) 8 (20) 2 (5) 5 (12.5) 
 
AC: acid; NA: non acid; n: expressed as median and range 
 
Table 2. K values with standard error (SE) and percentage of discordance (in brackets) between 
observers with regards to the number of reflux episodes divided into acid/non acid and mixed 
(liquid + gas). 
 Number of reflux episodes 
Acid Non Acid Liquid Mixed 
Observer 1 
Vs 
Observer 2 
 
0.69; SE 0.02  
(11%) 
 
0.32; SE 0.19 
(14%) 
 
0.74; SE 0.12 
 (9%) 
 
0.40; SE 0.19 
(16%) 
Observer 1 
Vs 
Observer 3 
 
0.89; SE 0.18  
(4%) 
 
0.40; SE 0.23  
(16%) 
 
     0.82; SE 0.18 
 (6%) 
 
0.36; SE 0.19 
(17.5%) 
Observer 2 
Vs 
Observer 3 
 
0.72; SE 0.18 
 (9.5%) 
 
0.36; SE 0.12 
 (17.5%) 
 
0.70; SE 0.20 
 (9.5%) 
 
0.30; SE 0.23 
(14.5%) 
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Table 3. K values with standard error (SE) and percentage of discordance (in brackets) between the 
first and the second analysis with regards to the number of reflux episodes divided into acid/non 
acid and mixed (liquid + gas). 
 Number of reflux episodes 
Acid Non Acid Liquid Mixed 
Observer 1 
 
 
 
 
0.64; SE 0.08 
(1.8%) 
 
0.32; SE 0.04 
(17.9%) 
 
0.36; SE 0.05 
(13.7%) 
 
0.41; SE 0.04 
(9.2%) 
Observer 2  
0.68; SE 0.03 
(7.6%) 
 
0.84; SE 0.01 
(7.6%) 
 
0.84; SE 0.02 
(8.1%) 
 
0.83; SE 0.01 
(7.4%) 
 
Observer 3  
0.85; SE 0.07 
(0.4%) 
 
0.4; SE 0.05 
(7.7%) 
 
0.47; SE 0.09 
(4.4%) 
 
0.49; SE 0.05 
(4.3%) 
 
 
Table 4. K values with standard error (SE) and percentage of discordance (in brackets) between 
observers, with regards to S.I. and S.A.P. divided into acid/non acid 
 S.I. S.A.P. 
Acid Non Acid Acid Non Acid 
Observer 1 
Vs 
Observer 2 
 
1.0; SE 0  
(0%) 
 
-  
(5%) 
 
1.0; SE 0 
 (0%) 
 
0.35; SE 0.19 
(15%) 
Observer 1 
Vs 
Observer 3 
 
1.0; SE 0  
(0%) 
 
-  
(7.5%) 
 
1.0; SE 0 
 (0%) 
 
0.36; SE 0.19 
(17.5%) 
Observer 2 
Vs 
Observer 3 
 
1.0; SE 0 
 (0%) 
 
- 
 (5%) 
 
1.0; SE 0 
 (0%) 
 
0.23; SE 0.23 
(12.5%) 
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Table 5. K values with standard error (SE) and percentage of discordance (in brackets) between the 
first and the second analysis, with regards to S.I. and S.A.P. divided into acid/non acid 
 S.I. S.A.P. 
Acid Non Acid Acid Non Acid 
Observer 1 0.77; SE 0.15 
(5%) 
0.65; SE 0.31 
(2.5%) 
0.80; SE  0.13 
(5%) 
0.48; SE 0.18 
(15%) 
Observer 2 0.77; SE 0.15 
(5%) 
- 
(5%) 
0.72; SE 0.15 
(7.5%) 
0.79; SE 0.20 
(2.5%) 
 
Observer 3 1.0; SE 0 
(0%) 
- 
(2.5%) 
1.0; SE 0 
(0%) 
0.54; SE 0.20 
(10%) 
 
 
Table 6. Percentage of agreement with confidence interval (in brackets) between short and 
traditional analysis. 
 S.I. S.A.P. 
Acid Non Acid Acid Non Acid 
Observer 1 87.5 
(72-95) 
100 
(9-100) 
100 
(91-100) 
97.5 
(85-100) 
Observer 2 90.0 
(75-97) 
95 
(82-99) 
97.5 
(85-100) 
          92.5 
(78-98) 
 
Observer 3 87.5 
(72-95) 
100 
(91-100) 
100 
(91-100) 
100 
(91-100.0) 
 
 
 
 
 
 
 
   
   27 
 
FIGURES 
Figure. 1. Oesophageal impedance-pH catheter.  
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